"With their broad and extensive industry experience, we are very fortunate to have both Mr. Schneider and Mr. Woods as members of our board of directors," stated Jack Lief, Arena's President and Chief Executive Officer. "We welcome their leadership and look forward to continuing to apply the entire board's expertise to best support Arena's efforts to build stockholder value as it matures and moves closer to the expected filing of its first NDA."
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, development,
preclinical and internal and partnered clinical programs, ability to
develop compounds and commercialize drugs and about building value and
filing an NDA. For su
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved